SensID product development in collaboration with Qiagen

21. April 2020Press releases

Rostock, 7th of April 2020  SensID GmbH, a Germany based provider of controls and reference materials for clinical genomics, today announces that it has developed a set of controls for the US FDA approved and CE-IVD marked therascreen PIK3CA RGQ PCR Kits from QIAGEN.  The CE-IVD therascreen PIK3CA RGQ PCR Kit was launched in Europe in February 2020 as an aid to the identification of activating PIK3CA mutations in samples of either FFPE tumour tissue or … Read More

SensID Inks Distribution Agreement with TATAA Biocenter for its MDx Reference Standards

14. May 2019Press releases

SensID GmbH, a leading specialist in the development and manufacturing of high quality reference standards for molecular diagnostics, and TATAA Biocenter AB, a pioneer within the industry and leading provider of high quality molecular analyses announced today the signing of a distribution agreement. SensID gives TATAA full access to its continuously growing product portfolio for … Read More